Marlon V. Duro

Marlon V. Duro

Auto-generated profile, based on publicly available information

Marlon V. Duro

Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
BEBrandon Ebright
Brandon Ebright
MDMarlon V. Duro
Marlon V. Duro
KCKai Chen
Kai Chen
SLStan Gee Louie
Stan Gee Louie
HYHussein N. Yassine
Hussein N. Yassine

22 March 2023 in Journal of Lipid Research
Verified
Journal Article
Open access
MBMikaila Ann Bantugan
Mikaila Ann Bantugan
HXHaotian Xian
Haotian Xian
VSVictoria Solomon
Victoria Solomon
MLMitchell Lee
Mitchell Lee
ZCZhiheng Cai
Zhiheng Cai
HYHussein N. Yassine
Hussein N. Yassine
Apolipoprotein ε allele 4 (APOE4) influences the metabolism of polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA). The entorhinal cortex (EC) in the brain is affected early in Alzheimer's disease and is rich in DHA. The purpose of this study is to identify the effect of APOE4 and DHA lipid species on the EC. Plasma and cerebrospinal fluid (CSF) lipidomic measurements were obtained from the DHA Brain Delivery Pilot, a randomized clinical trial of DHA supplementation (n = 10) versus placebo (n = 12) for six months in nondemented older adults stratified by APOE4 status. Wild-type C57B6/J mice were fed a high or low DHA diet for 6 months followed by plasma and brain lipidomic analysis. Levels of phosphatidylcholine DHA (PC 38:6) and cholesterol ester DHA (CE 22:6) had the largest increases in CSF following supplementation (P < 0.001). DHA within triglyceride (TG) lipids in CSF strongly correlated with corresponding plasma TG lipids, and differed by APOE4, with carriers having a lower increase than noncarriers. Changes in plasma PC DHA had the strongest association with changes in EC thickness in millimeters, independent of APOE4 status (P = 0.007). In mice, a high DHA diet increased PUFAs within brain lipids. Our findings demonstrate an exchange of DHA at the CSF-blood barrier and into the brain within all lipid species with APOE having the strongest effect on DHA-containing TGs. The correlation of PC DHA with EC suggests a functional consequence of DHA accretion in high density lipoprotein for the brain.

19 June 2026 in EBioMedicine
Verified
Journal Article
Open access
HYHussein N. Yassine
Hussein N. Yassine
SPSara Ghasem Pour
Sara Ghasem Pour
MJMarlene Juarez
Marlene Juarez
IAIsabella C. Arrelanas
Isabella C. Arrelanas
NANada Ali
Nada Ali
LSLon S. Schneider
Lon S. Schneider
APOE ε4 carriers have increased Alzheimer's disease risk and altered omega-3 metabolism. No large-scale prevention trials have tested high-dose docosahexaenoic acid (DHA) supplementation specifically in non-demented APOE ε4 carriers with low baseline omega-3 intake for early intervention. We conducted a phase IIa 24-month, randomised, double-blind, placebo-controlled trial (NCT03613844) at the University of Southern California between September 2018 and May 2024. Participants aged 55-80 years without dementia, low dietary DHA intake (<200 mg/day), and ≥1 dementia risk factor were stratified by cerebrospinal fluid (CSF) collection willingness into lumbar puncture (LP) or no-LP arms. Within each arm, participants were randomised 1:1 to receive 2 g/day DHA or placebo, stratified by APOE ε4 status. Primary outcome was the 6-month CSF DHA-to-arachidonic acid (AA) ratio change. Secondary and exploratory outcomes included 24-month neuroimaging and cognitive measures. Of 739 screened individuals, 365 participants were randomised (181 LP arm, 184 no-LP arm). Mean age was 66.4 years (SD 5.7), 210 (58%) were female, 142 (39%) were Hispanic, 173 (47%) were APOE ε4 carriers. DHA supplementation increased CSF DHA/AA ratio at 6 months vs placebo (0.17 [95% CI 0.15-0.18] vs -0.02 [95% CI -0.04 to -0.0004]; difference 0.19 [95% CI 0.16-0.21]; p < 0.0001), independent of APOE ε4 status (interaction p = 0.71). Dropout was 38%, mainly due to COVID-19. No treatment differences were observed in brain volumes or cognitive performance over 24 months. Adverse events were comparable between groups, with no serious adverse events attributed to treatment. High-dose DHA achieved CNS target engagement in non-demented older adults with low baseline omega-3 intake, independent of APOE ε4. Despite biochemical target engagement, no differences in cognition or brain structure were observed over 24 months. Future research should prioritise brain DHA metabolism over further supplementation trials. National Institute on Aging (R01AG057684) and the ADDF (GC-201711-2014197).

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SWShaowei Wang
Shaowei Wang
BEBrandon Ebright
Brandon Ebright
MDMarlon Vincent V. Duro
Marlon Vincent V. Duro
ZCZhiheng Cai
Zhiheng Cai
JGJasmin Galvan
Jasmin Galvan
HYHussein N. Yassine
Hussein N. Yassine
Background: Neuroprotective nutritional interventions involving greater consumption of polyunsaturated fats (Mediterranean diet, fish consumption or DHA supplements) are less effective in APOE4 carriers with dementia compared to non‐carriers. We recently demonstrated greater activation of calcium dependent phospholipase A2 (cPLA2) in APOE4 compared with non‐APOE4 using both postmortem human brains and in brain tissues from APOE4 animal models. Activation of cPLA2 is associated with lower omega‐3 brain levels and lower measures of blood‐brain barrier (BBB) integrity as assessed using 7T DCE MRI to derive contrast transfer values (K trans).Method: Here, we present new data on aging (18 months) old APOE mouse models on a low DHA diet, APOE4‐TR mice treated with LPS and APOE knock out mice as a model of lower BBB integrity. All models were treated with the brain penetrant cPLA2 inhibitor ASB14780 at 10 mg/kg IP daily over 8 weeks in the aging model and acutely (7 days) in the younger LPS and APOE KO models.Result: cPLA2 inhibition was associated with increased brain omega‐3 levels in both the aging APOE4 model and in the younger APOE4 mice treated acutely with LPS. In the aging APOE4 mouse model, cPLA2 inhibition associated with better performance on novel object recognition, improved synaptic markers, and lower microglial activation. In the APOE KO model, treatment was associated with improved measures of BBB with lower K trans following treatment (Figure).Conclusion: The results here demonstrate how neuroinflammation associated with APOE4 depletes brain omega‐3s via activation of cPLA2 and how reducing cPLA2 activity can rescue this phenotype. The development of specific and potent brain penetrant cPLA2 inhibitors promises to enhance the brain effects of omega‐3 enriched diets by limiting the effects of neuroinflammation on the aging APOE4 brain.